Search results for "platelet aggregation inhibitors"

showing 10 items of 105 documents

Gas chromatographic analysis of resveratrol in plasma, lipoproteins and cells after in vitro incubations

1998

Resveratrol is a trihydroxystilbene present in certain red wines. It may play a role in the inhibition of lipoprotein oxidation and platelet activity. We have developed the first method to measure resveratrol in animal and human samples and to study its incorporation in vitro. After adding epicoprostanol as an internal standard, samples are subjected to lipid extraction in the presence of antioxidant and under dim light to minimize both denaturation and isomerization of the trans-resveratrol to the cis-form. Extracts were purified by cold acetone precipitation and the resveratrol-containing acetone phase was evaporated under nitrogen. The resveratrol was analyzed as a trimethylsilyl derivat…

Chromatography GasErythrocytesAntioxidantendocrine system diseasesmedicine.medical_treatmentResveratrolSensitivity and Specificitychemistry.chemical_compoundStilbenesAcetonemedicineAnimalsHumansPlatelet activationLipoprotein oxidationDetection limitChromatographyorganic chemicalsReproducibility of Resultsfood and beveragesStereoisomerismGeneral ChemistryRatsLipoproteins LDLchemistryResveratrolCalibrationLinear ModelsGas chromatographyQuantitative analysis (chemistry)Platelet Aggregation InhibitorsJournal of Chromatography B: Biomedical Sciences and Applications
researchProduct

Oral Glycoprotein IIb/IIa Antagonists for Unstable Angina — Is There Still a Chance for the Oral Substances?

2001

The intravenous glycoprotein IIb/IIIa antagonists abciximab, tirofiban and eptifibatide are well accepted for the therapy of patients with unstable angina and/or as concomitant medication during coronary interventions. Despite the fact that these drugs are not used in all patients presenting with unstable angina during coronary interventions, the scientific evidence is overwhelming including the substantial reduction in mortality 3 years after utilisation of abciximab for coronary interventions in patients with unstable angina. In addition to these two indications, intravenous glycoprotein IIb/IIIa antagonists are currently being investigated for use in patients undergoing carotid artery in…

Clinical Trials as Topicmedicine.medical_specialtyUnstable anginaFibrinogen receptorbusiness.industryAdministration OralPlatelet Glycoprotein GPIIb-IIIa ComplexHematologyTirofibanmedicine.diseaseAnginaInternal medicinemedicineAbciximabCardiologyEptifibatideHumansAngina UnstableMyocardial infarctionbusinessStrokePlatelet Aggregation Inhibitorsmedicine.drugThrombosis Research
researchProduct

Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in…

2021

Abstract Background There is mounting evidence on the existence of a Pediatric Inflammatory Multisystem Syndrome-temporally associated to SARS-CoV-2 infection (PIMS-TS), sharing similarities with Kawasaki Disease (KD). The main outcome of the study were to better characterize the clinical features and the treatment response of PIMS-TS and to explore its relationship with KD determining whether KD and PIMS are two distinct entities. Methods The Rheumatology Study Group of the Italian Pediatric Society launched a survey to enroll patients diagnosed with KD (Kawasaki Disease Group – KDG) or KD-like (Kawacovid Group - KCG) disease between February 1st 2020, and May 31st 2020. Demographic, clini…

Coronary artery abnormalities; Hypotension; Kawasaki disease; Multisystem inflammatory syndrome associated with coronavirus disease; Myocarditis; Pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection; SARS-CoV-2; Age Distribution; Antirheumatic Agents; Aspirin; C-Reactive Protein; COVID-19; Child; Child Preschool; Coronary Artery Disease; Cough; Diarrhea; Dyspnea; Female; Glucocorticoids; Heart Failure; Humans; Hyperferritinemia; Hypotension; Immunoglobulins Intravenous; Immunologic Factors; Infant; Intensive Care Units Pediatric; Interleukin 1 Receptor Antagonist Protein; Italy; Lymphopenia; Male; Mucocutaneous Lymph Node Syndrome; Myocarditis; Platelet Aggregation Inhibitors; SARS-CoV-2; Shock; Systemic Inflammatory Response Syndrome; Tachypnea; Troponin T; VomitingMalelcsh:Diseases of the musculoskeletal systemcoronary artery abnormalities; hypotension; kawasaki disease; multisystem inflammatory syndrome associated with coronavirus disease; myocarditis; pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection; SARS-CoV-2; age distribution; antirheumatic agents; aspirin; C-reactive protein; COVID-19; child ; preschool; coronary artery disease; cough; diarrhea; yspnea; female; glucocorticoids; heart failure; humans; hyperferritinemia; hypotension; immunoglobulins; intravenous; immunologic factors; infant; intensive care units; pediatric; interleukin 1 receptor antagonist protein; italy; lymphopenia; male; mucocutaneous lymph node syndrome; myocarditis; platelet aggregation inhibitors; SARS-CoV-2; shock; systemic inflammatory response syndrome; tachypnea; troponin T; vomitingMyocarditiCoronary Artery Disease030204 cardiovascular system & hematologySARS-CoV-2 Kawasaki disease Pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection Myocarditis Hypotension Multisystem inflammatory syndrome associated with coronavirus disease Coronary artery abnormalitiesCoronary artery diseaseSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineGlucocorticoidImmunologic FactorMultisystem inflammatory syndrome associated with coronavirus diseaseImmunology and AllergyChildCoronary artery abnormalitieFisher's exact testPediatricTachypneabiologylcsh:RJ1-570Antirheumatic AgentImmunoglobulins IntravenousShockPediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infectionSettore MED/38Systemic Inflammatory Response SyndromeIntensive Care UnitsMyocarditisC-Reactive ProteinItalyAntirheumatic AgentsChild PreschoolCohortsymbolsPlatelet aggregation inhibitorFemaleHypotensionIntravenousCoronary artery abnormalitiesHumanResearch ArticleDiarrheamedicine.medical_specialtyMyocarditisVomitingImmunoglobulinsMucocutaneous Lymph Node SyndromeIntensive Care Units Pediatric03 medical and health sciencessymbols.namesakeAge DistributionRheumatologyTroponin TInternal medicineLymphopeniamedicineHumansImmunologic FactorsPreschoolGlucocorticoids030203 arthritis & rheumatologyHeart FailureAspirinKawasaki diseasebusiness.industrySARS-CoV-2Platelet Aggregation InhibitorC-reactive proteinCOVID-19Infantlcsh:Pediatricsmedicine.diseaseSystemic inflammatory response syndromeInterleukin 1 Receptor Antagonist ProteinDyspneaCoughImmunoglobulins IntravenouPediatrics Perinatology and Child Healthbiology.proteinKawasaki diseaseHyperferritinemialcsh:RC925-935businessPlatelet Aggregation InhibitorsPediatric rheumatology online journal
researchProduct

Number of drugs used in secondary cardiovascular prevention and late survival in the population of Valencia Community, Spain.

2019

Abstract Background Drug treatment for secondary prevention of cardiovascular disease is recommended by guidelines, but it is not always followed in real life. This study wanted to assess the size of this gap and its impact on mortality in subjects after a cardiovascular event (MACE). Methods Patients with any of MACE in the period from January 1st 2011 to December 31st 2013, and more than one year of follow-up were selected from population of the Valencian Community. Drugs for secondary prevention were antiplatelets, renin-angiotensin system blockers and statins. Assessment of treatment was performed one year after the initial event. Mortality risk was assessed using Cox by the number of d…

DrugMalemedicine.medical_specialtyMedication Therapy Managementmedia_common.quotation_subjectmedicine.medical_treatmentPopulationMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsDisease030204 cardiovascular system & hematologyRevascularizationRisk Assessment03 medical and health sciencesAngiotensin Receptor Antagonists0302 clinical medicineInternal medicinemedicineSecondary PreventionHumans030212 general & internal medicineMyocardial infarctioneducationStrokemedia_commonAgededucation.field_of_studybusiness.industryConfoundingmedicine.diseaseSurvival AnalysisProfessional Practice GapsStrokeSpainFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessMacePlatelet Aggregation InhibitorsInternational journal of cardiology
researchProduct

Biowaiver monograph for immediate-release solid oral dosage forms: acetylsalicylic acid.

2012

A biowaiver monograph for acetylsalicylic acid (ASA) is presented. Literature and experimental data indicate that ASA is a highly soluble and highly permeable drug, leading to assignment of this active pharmaceutical ingredient (API) to Class I of the Biopharmaceutics Classification System (BCS). Limited bioequivalence (BE) studies reported in the literature indicate that products that have been tested are bioequivalent. Most of the excipients used in products with a marketing authorization in Europe are not considered to have an impact on gastrointestinal motility or permeability. Furthermore, ASA has a wide therapeutic index. Thus, the risks to the patient that might occur if a nonbioequi…

Drugmedia_common.quotation_subjectPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyBioequivalenceMarketing authorizationDosage formDrug StabilityFibrinolytic AgentsAnimalsHumansCyclooxygenase Inhibitorsmedia_commonActive ingredientAspirinChemistryAnti-Inflammatory Agents Non-SteroidalBiopharmaceutics Classification SystemSolubilityTherapeutic EquivalencyPlatelet aggregation inhibitorCaco-2 CellsFibrinolytic agentPlatelet Aggregation InhibitorsTabletsJournal of pharmaceutical sciences
researchProduct

The pleiotropic effects of antiplatelet therapies

2019

Percutaneous coronary intervention is the most often used method for coronary revascularization. Stenting restores blood perfusion to ischemic areas, but it also causes mechanical disruption of the atheromatous plaque and the nearby endothelium, stimulating the activation of platelets. In a similar way, platelets are activated by thrombin exposure in the setting of plaque rupture. The interaction between platelets, oxidative stress and inflammation is an important factor determining the extent and severity of vascular dysfunction observed in these settings. Platelets activated by the vessel trauma release inflammatory and mitogenic mediators into the vascular microenvironment, activating le…

EndotheliumPhysiologyInflammation030204 cardiovascular system & hematologyPharmacologymedicine.disease_cause030218 nuclear medicine & medical imagingNitric oxide03 medical and health scienceschemistry.chemical_compound0302 clinical medicineThrombinPhysiology (medical)medicineHumansPlateletEndotheliumPlatelet activationHemostasisbusiness.industryHematologyPlatelet Activationmedicine.anatomical_structurechemistrymedicine.symptomCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsOxidative stressLeukocyte chemotaxismedicine.drugClinical Hemorheology and Microcirculation
researchProduct

Mediterranean Diet Decreases the Initiation of Use of Vitamin K Epoxide Reductase Inhibitors and Their Associated Cardiovascular Risk: A Randomized C…

2020

Our aim is to assess whether following a Mediterranean Diet (MedDiet) decreases the risk of initiating antithrombotic therapies and the cardiovascular risk associated with its use in older individuals at high cardiovascular risk. We evaluate whether participants of the PREvenci&oacute

Male0301 basic medicineVitamin KTime FactorsMediterranean diet030204 cardiovascular system & hematologyPharmacology4-HydroxycoumarinsDiet Mediterraneanchemistry.chemical_compound0302 clinical medicinepreventionAntithromboticNutsEnzyme InhibitorsDiet Fat-RestrictedUncategorizedNutrition and DieteticsMiddle AgedClopidogrelVitamines KCardiovascular Diseasesrandomized controlled trialsRandomized controlled trialsPlatelet aggregation inhibitorDietaFemaleVitamin K epoxide reductaselcsh:Nutrition. Foods and food supplymedicine.druglcsh:TX341-641Article03 medical and health sciencesMediterranean cookingFibrinolytic AgentsMediterranean dietVitamin K Epoxide ReductasesPlatelet aggregation inhibitorsCuina mediterràniamedicineHumansTiclopidineplatelet aggregation inhibitorsOlive OilAgedMediterranean DietMalalties cardiovascularsbusiness.industryPreventionWarfarinDiet4-hydroxycoumarins030104 developmental biologychemistryHeart Disease Risk FactorsbusinessFood Science
researchProduct

The prescription of direct oral anticoagulants in the elderly: An observational study of 19 798 Ambulatory subjects.

2020

International audience; Objective Direct oral anticoagulants (DOACs) are increasingly prescribed to elderly people, but the epidemiologic data for this population remains scarce. We compared the elderly population taking DOACs and those not taking DOACs (noDOAC). Method We included individuals over 75 years old, affiliated to Mutualite Sociale Agricole of Burgundy (a French regional health insurance agency), who had been refunded for a prescribed DOAC between 1st and 30th September 2017. The DAOC group (DAOCG) and noDOAC group (noDOACG) were compared in terms of demographic conditions, registered chronic diseases (RCD), and number and types of prescribed drugs. In the DOACG, we compared the…

MaleAdministration Oral030204 cardiovascular system & hematologyKidney Function Tests0302 clinical medicineRivaroxabanMedicineDisease030212 general & internal medicineProspective StudiesPractice Patterns Physicians'Aged 80 and overeducation.field_of_studyFrailtyVenous ThromboembolismGeneral MedicineMetaanalysisManagement3. Good healthDabigatranHealthCreatinineAmbulatoryPlatelet aggregation inhibitorApixabanFemaleBlood Coagulation TestsFranceSafetymedicine.drugmedicine.medical_specialtyPyridonesPopulationDrug PrescriptionsDabigatran03 medical and health sciencesInternal medicineHumansMedical prescriptioneducationAntihypertensive AgentsAgedRivaroxabanbusiness.industryWarfarinAnticoagulantsBlood Cell CountAtrial-FibrillationChronic DiseasePyrazolesWarfarinbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyPlatelet Aggregation InhibitorsInternational journal of clinical practiceREFERENCES
researchProduct

''Assessment of the use of hypolipidemic agents (HAs), mainly statins, in elderly subjects aged 80 years and more in Burgundy: Analysis of 13,211 pat…

2012

Manckoundia, Patrick | Lorenzini, Mathieu | Disson-Dautriche, Anne | Petit, Jean-Michel | Lorcerie, Bernard | Debost, Emmanuel | Menu, Didier | Pfitzenmeyer, Pierre; International audience; ''Only few studies have investigated the use of HA in elderly subjects and there are no data in very elderly subjects. We assessed the prescription of HA and analyzed the relationship between such prescriptions and frailty markers among persons aged 80 and more in an observational study. We recorded the prescriptions for 13,211 patients aged 80-109 years and affiliated to the "Mutualite-Sociale-Agricole (MSA)'' of Burgundy over a 1-month period. The prescription of a HA among all included patients, and t…

MaleAgingHealth (social science)DiseaseCoronary Artery Disease030204 cardiovascular system & hematologylaw.invention0302 clinical medicineRandomized controlled triallawAVERAGE CHOLESTEROL LEVELS030212 general & internal medicineStrokeHypolipidemic AgentsAged 80 and overFibric AcidsOPEN-LABEL3. Good healthCONTROLLED TRIALHypertensionFemaleFranceSTROKEmedicine.drugmedicine.medical_specialtyAdrenergic beta-AntagonistsDrug Prescriptions03 medical and health sciencesPeripheral Arterial DiseaseDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumansCORONARY-HEART-DISEASEMedical prescriptionCARDIOVASCULAR EVENTSMORTALITY''Polypharmacybusiness.industryMORTALITY[SCCO.NEUR]Cognitive science/NeuroscienceCardiovascular Agentsmedicine.disease''CORONARY-HEART-DISEASEPRAVASTATINPhysical therapyPolypharmacyRISK-FACTORSObservational studyGeriatrics and GerontologyHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPRIMARY PREVENTIONGerontologyPravastatinPlatelet Aggregation Inhibitors
researchProduct

Prescription of Antithrombotic Therapy in Older Patients Hospitalized for Transient Ischemic Attack and Ischemic Stroke: The GIFA Study

2004

Background and Purpose— Antithrombotic therapy has been demonstrated as an effective tool for secondary ischemic stroke prevention. Nevertheless, scant data are available on actual prescription of this therapy in clinical practice. Methods— A total of 17 337 patients admitted to geriatric and internal medicine wards participating in the study in the 1993 to 1998 survey period were analyzed. Patients with coded diagnoses of ischemic stroke and transient ischemic attack (TIA) were selected. Data recorded included demographic and clinical characteristics and medication prescription during hospital stay and at discharge. Logistic regression analyses were used to identify conditions associated …

MaleAgingmedicine.medical_specialtypharmacoepidemiologyEpidemiologymedicine.drug_classIschemiaMedication prescriptionNOBrain Ischemiastroke; prevention; aging; antithrombotic therapy; pharmacoepidemiologypreventionFibrinolytic AgentsEpidemiologyAntithromboticmedicineHumansMedical prescriptionStrokeAgedDemographyAntithrombotic therapyAdvanced and Specialized Nursingbusiness.industryAnticoagulantAnticoagulantsOdds ratiomedicine.diseaseHospitalizationStrokeIschemic Attack TransientAcute DiseaseEmergency medicinePhysical therapyFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsStroke
researchProduct